Southern California Institute For Research And Education

Southern California Institute For Research And Education, a tax-exempt nonprofit research organization based in Long Beach, California, conducts biomedical and translational research as a prime recipient of federal grants (60% of recent awards) and as a sub-recipient on multi-institutional projects (40% of recent awards). The organization operates within the National Institutes of Health and HHS ecosystem, with no federal contracting footprint.

The organization's research portfolio centers on bone biology, immunology, and cancer therapeutics. As a prime recipient, SCIRE has received three recent project grants: a $337,072 award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (CFDA 93.846) issued June 19, 2026, to study cellular and molecular mechanisms of CCDC120-associated osteopetrosis, with performance through March 31, 2031; a completed grant from NIAMS for systems genetics approaches to identifying osteoclast endocrine and paracrine communications, running through August 31, 2026; and a grant from the National Cancer Institute awarded July 14, 2022, for identifying novel therapies targeting Merkel cell carcinoma, completing June 30, 2027. Work is performed in Long Beach, California.

Customer concentration is tightly clustered within the Department of Health and Human Services. The top five funding agencies, accounting for 76% of the award count, are the National Cancer Institute (5 awards), the National Institutes of Health general pool (4 awards), the National Institute on Alcohol Abuse and Alcoholism (4 awards), the Centers for Disease Control and Prevention (3 awards), and NIAMS (3 awards). SCIRE has no parent contract vehicles and does not compete for federal contracts or task orders.

In its sub-recipient role, SCIRE partners with research universities and medical centers including University of California Irvine, University of Pittsburgh, Cedars-Sinai Medical Center, and Oregon Health and Science University on clinical translational science and cancer detection initiatives. Recent sub-grant work includes participation in a VA Long Beach partnership within the UCI Institute for Clinical and Translational Science (awarded October 1, 2025, and recurring through 2024), bladder cancer biomarker detection studies with Cedars-Sinai (October 8, 2025, and August 30, 2024), and the SWOG Network Group Operations Center of the National Cancer Institute's National Clinical Trials Network through Oregon Health and Science University (April 7, 2025, and May 13, 2024). Combined potential value across all 25 awards is $14.6 million. Only one award reaches ultimate completion within the next twenty-four months, presenting minimal recompete pressure through 2027.